Menu Search
Equities

argenx SE

ARGX:BRU

argenx SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)482.20
  • Today's Change6.50 / 1.37%
  • Shares traded55.49k
  • 1 Year change-1.35%
  • Beta0.6179
Data delayed at least 15 minutes, as of Sep 19 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform14
Hold1
Sell0
Strong Sell1

Share price forecast in USD

The 17 analysts offering 12 month price targets for argenx SE have a median target of 529.83, with a high estimate of 592.22 and a low estimate of 153.50. The median estimate represents a 9.88% increase from the last price of 482.20.
High22.8%592.22
Med9.9%529.83
Low-68.2%153.50

Dividends

Dividend information is not available for argenx SE.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Jul 25, 2024, argenx SE reported 2nd quarter 2024 earnings of 0.45 per share. This result exceeded the -0.97 consensus loss of the 17 analysts covering the company and outperformed last year's 2nd quarter results by 2.14.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate+9.91%
argenx SE reported annual 2023 losses of -5.16 per share on Feb 29, 2024.
Average growth rate-40.29%
More ▼

Revenue history & estimates in USD

argenx SE had 2nd quarter 2024 revenues of 489.43m. This bettered the 439.48m consensus of the 17 analysts covering the company. This was 113.02% above the prior year's 2nd quarter results.
Average growth rate+15.31%
argenx SE had revenues for the full year 2023 of 1.27bn. This was 184.91% above the prior year's results.
Average growth rate+211.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.